In our previous blogs we discussed the need for a more comprehensive approach for monitoring contaminants in finished drug products.1,2 Here we cover a generalized approach for the targeted, quantitative LC-MS/MS analysis of several commonly encountered nitrosamines in pharmaceuticals and ways to address specific challenges with their analysis.
Tags
Pharma perspectives: The influence of LC-MS innovation on drug development outsourcing
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Working for a contract research organization and more recently for SCIEX has provided an interesting perspective on trends the market experiences that affect many of us.
Want to accelerate your drug discovery workflow?
Bringing a new drug to market is a costly and complex process. With potentially hundreds of thousands of new compounds to screen during drug discovery, sample throughput is a common bottleneck for pharmaceutical companies. So how do you overcome this barrier?
Easing the demands of a compliant pharmaceutical laboratory
At SCIEX, we are proud to provide analytical systems to the pharmaceutical industry. We work hard to understand the demands of analytical work and the processes required to develop and manufacture drugs.
What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)
SCIEX was very proud to have an illustration of the Acoustic Ejection Mass Spectrometry (AEMS) technology that powers the Echo® MS system on the front cover of the Journal of the American Society for Mass Spectrometry in January 2023. The associated article—Ultrahigh-Throughput Intact Protein Analysis with Acoustic Ejection Mass Spectrometry—was co-authored by scientists from SCIEX and Merck.
5 Reasons to choose the Echo® MS system for high-throughput drug discovery
Have you thought about introducing new technology into your high-throughput drug discovery lab? Here are 5 reasons the Echo® MS system could make a difference for you.
What have we learned from the nitrosamine crisis?
The pharmaceutical industry is facing an ongoing issue with genotoxic impurities (GTIs). Over the past year, we have witnessed genotoxic impurities affect several drugs, including those used to treat elevated blood pressure, heartburn and acid reflux. Angiotensin II...
Top 7 Echo® MS system customer questions—answered
You asked, we answered! With analysis speeds of at least 1 sample per second, the Echo® MS system has created a buzz in the industry. This is up to 50x faster than conventional LC-MS/MS. This revolutionary tool for drug discovery and development has led to...
An interview from the Science Explorer about the Echo® MS system
The Science Explorer interviews Neil Walsh from SCIEX to discuss the significant application areas of the Echo® MS System and what makes this system so attractive to biopharmaceutical laboratories.
Developing a method for nitrosamine analysis in pharmaceutical products
In our previous blogs we discussed the need for a more comprehensive approach for monitoring contaminants in finished drug products.1,2 Here we cover a generalized approach for the targeted, quantitative LC-MS/MS analysis of several commonly encountered nitrosamines in pharmaceuticals and ways to address specific challenges with their analysis.
The Echo® MS system: Is it reproducible? Yes… yes… yes!
The Echo® MS System is an exciting new platform that dramatically speeds sample analysis for quantitative MS studies. Because of its unique and innovative technology, the system can analyze samples faster than ever before—but without the need for LC.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.